New applications for the botulinum toxin;Nuevas aplicaciones de la toxina botulinica

Neurologia

Volumn 13, Issue 8, 1998, Pages 388-394

  Lopez Del Val L J ^a,b   Morales Asin F ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

BLEPHAROSPASM; DRUG INDICATION; DRUG MECHANISM; HUMAN; HUMAN TISSUE; OPHTHALMOPLEGIA; REVIEW; TREATMENT INDICATION; URINARY TRACT DISEASE;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; FEMALE; HUMANS; MALE;

EID: 0031787525     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Grandas F. Aplicaciones clínicas de la toxina botulínica. Neurología 1995; 10: 224-233.
2. Tsui J, Bhatt M, Calne S, Calne D. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology 1993; 43: 183-185.
3. American Academy of Otolaryngology. Position statement on the clinical usefulness of botulinum toxin in the treatment of spasmodic dysphonia. Arch Otolaryngol Head Neck Surg Bull 1990; 9: 8.
4. Blitzer A, Brin M, Stewart C, Aviv JE, Fahn S. Abductor laryngeal dystonia: a series treated with botulinum toxin. Laryngoscope 1992; 102: 163-167.
5. García Ruiz P, Samartín V, Urcelay V, Sánchez V. Utilidad de la toxina botulínica en la parálisis infantil. Neurologfa 1994; 9: 444.
6. Koman LA, Mooney JF, Smith BP, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A-toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14: 299-303.
7. Pascual-Pascual SI, Sánchez de Muniain P, Roche MC, Pascual-Castroviejo I. La toxina botulínica en el tratamiento de la parálisis cerebral infantil. Rev Neurol (Barc) 1997; 25: 1.369-1.375.
8. Sánchez Carpintero R, Narbona J. Toxina botulínica en el tratamiento de la espasticidad de la parálisis cerebral infantil. Resultados en 27 casos durante un año. Rev Neurol (Barc) 1997; 25: 531-535.
9. Borg-Stein J, Pine Z, Millaer J, Brin M. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am J Phys Med Rehabil 1993; 72: 364-368.
10. Grazko M, Polo K, Jabbari B. Botulinum toxin A and spasticity. Mov Disord 1994; 9 (Supl 1): 128.
11. Pierson SH, Katz DT, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 1996; 77: 717-721.
12. Girlanda P, Quartarone A, Sinicropi S, Nicolosi C, Roberto ML, Picciolo G et al. Botulinum toxin in upper limb spasticity: study of reciprocal inhibition between forearm muscles. Neuroreport 1997; 8: 3.039-3.044.
13. Simpson DM, Alexander DN, O'brien CF, Tagliati M, Asward AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controled trial. Neurology 1996; 46: 1.306-1.310.
14. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor sphincter dyssynergia in spinal cord injury patientes. J Urol 1988; 139: 919-922.
15. Schurch B, Hauri D, Largo M, Kreienbühl B, Meyer E, Rossier AB. Effects de la toxine botulinique A sur le sphincter strié periurétral des vessies neurogènes. J Urol 1990; 96: 375.
16. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990; 71: 24-26.
17. Schurch B, Hauri D, Rodic A, Curt M, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996; 155: 1.023-1.029.
18. Steinhardt GF, Naseer S, Cruz O. Botulinum toxin: novel treatment for dramatic urethral dilatation associated with dysfunctional voiding. J Urol 1997; 158: 190-191.
19. Huber A. Use of botulinum toxin in ophthalmology. Klin Monatsbl Augenheilkd 1997; 210: 289-292.
20. Kushner BJ. Botulinum toxin management of essential infantile esotropia in children. Arch Ophthalmol 1997; 115: 1.458-1.459.
21. Newman NJ, Lambert SR. Botulinum toxin treatment of supranuclear ocular motility disorders. Neurology 1992; 42: 1.391-1.393.
22. Rebolleda G, Muñoz Negrete FJ. Botulinum toxin treatmente of Hertwing-Magendie sign. Eur J Ophthalmol 1996; 6: 217-219.
23. Ruben ST, Lee JP, O'Neil D, Dunlop Y, Elston JS. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. Ophthalmology 1994; 101: 783-787.
24. Tomsak RT, Remler BF, Averbuch-Heller T, Chandran M, Leigh RJ. Unsatisfactory treatment of acquired mystagmus with retrobulbar injection of botulinum toxin. Am J Opthalmol 1995; 119: 489-496.
25. Arens LJ, Goldschmidt RB, Leary PM. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997; 39: 491-492.
26. Pullman SL, Parkinson G, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996; 53: 617-624.
27. Blitzer A, Brin M, Keen M, Aviv J. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arh Otolaryngol Head Neck Surg 1993; 119: 1.018-1.022.
28. Carruthers JDA, Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18: 17-21.
29. Carruthers A, Carruthers JDA. Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles. En: Carruthers A, Carruthers JDA, editores. Facial Stetic. Canadá: Vancouver, 1996; 46: 577-595.
30. Michelow BJ, Guyuron B. Rejuvenation the upper face. A logical gamut of surgical opinions. Clin Plast Surg 1997; 24: 199-212.
31. Ellis DA, Tan AK. Cosmetic upper-facial rejuvenation with botulinum toxin. J Otolaryngol 1997; 26: 92-96.
32. Guerrissi J, Sarkissian P. Local injection into mimetic muscles of botulinum toxin A for the treatment of facial lines. Ann Plast Surg 1997; 39: 447-453.
33. Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymetry caused by facial Bell's nerve paralysis. Plast Reconst Surg 1989; 84: 353-355.
34. Bikhazi NB, Maas CS. Refinement in the rehabilitation of the paralyzed face using botulinum toxin. Otolaryngol Head Neck Surg 1997; 117: 303-307.
35. Borodie GE, Pearce LB, Cheney M, Metson R, Brownstone D, Townsend D et al. Botulinum A toxin for treatment of aberrant facial nerve regeneration. Plast Reconstr Surg 1993; 91: 1.042-1.045.
36. Moore AP, Wood GD. Medical treatment of recurrent temporomandibular dislocation using botulinun toxin A. Br Dent J 1997; 183: 415-417.
37. Laskawi R. Combination of hypoglossal-facial nerve anastomosis and botulinum toxin injections to optimize mimic rehabilitation after removal of acoustic neurinomas. Plast Reconstr Surg 1997; 99: 1.006-1.011.
38. Borodie GE, Cheney M, McKenna M. Contralateral injections of botulinum toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg 1992; 90: 972-977.
39. Bushara KO, Park DM, Jones JC, Schutta HS. Botulinum toxin: a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 1996; 21: 276-278.
40. Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997; 136: 548-552.
41. Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment: botulinum toxin A injections of the parotid glands. Med Hypotheses 1997; 48: 337-339.
42. Shaari CM, Sanders T, Wu BL, Biller HF. Rhinorrhea is decreased in dogs after nasal applications of botulinum toxin. Otolaryngol Head Neck Surg 1995; 112: 566-571.
43. Frey L. Le syndrome du nerf auriculo-temporal. Rev Neurol (París) 1923; 40: 97-104.
44. Schulze-Bonhage A, Schröder M, Ferbert A. Botulinum toxin in the therapy of gustatory sweating. J Neurol 1996; 243: 143-146.
45. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol (Stockholm) 1995; 115: 459-461.
46. Bjerkhoel A, Trobbe O. Prey's syndrome: treatment with botulinum toxin. J Laryngol Otol 1997; 111: 839-844.
47. Pasricha PJ, Ravich WJ, Hendrix TR. Treatment of achalasia with intrasphincteric injection of botulinum toxin: A pilot trial. Ann Intern Med 1994; 121: 590-591.
48. Dufour JF, Fawaz KA, Libby DE. Botulinum toxin injection for secondary achalasia with esophageal varices. Gastrointest Endosc 1997; 45: 191-193.
49. López P, Castiella A, Montalvo I, Bujanda L, Alzate LF, Gil I et al. Tratamiento de la acalasia con toxina botulínica. Rev Esp Enf Digest 1997; 89: 367-370.
50. Eaker EY, Gordon JM, Vogel SB. Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia. Dig Dis Sci 1997; 42: 724-727.
51. Kadakia SC, Wong RKM, Graded pneumatic dilatation using rigiflex achalasia dilator in patients with primary esophageal achalasia. Am J Gastroenterol 1993; 88: 34-38.
52. Parkman HP, Reynolds JC, Ouyang A, Nosato EF, Fisemberg JM, Cohen S. Pneumatic dilatation or esophagomyotomy. Treatment of idiopatic achalasia: clinical outcomes and cost analysis. Dig Dis Sci 1993; 38: 75-85.
53. Traube M. On drugs and dilators for achalasia. Dig Dis Sci 1991; 36: 257-259.
54. Vantrappen G, Hellemans J. Treatment of achalasia and related motor disorders. Gastroenterology 1980; 79: 144-154.
55. Vallera RA, Brazer SA. Botulinum toxin for suspected pseudo achalasia. Am J Gastroenterol 1995; 90: 1319-1321.
56. Ferrari AP Jr, Siqueira ES, Brant CQ. Treatment of achalasia in Chagas disease with botulinum toxin. N Engl J Med 1995; 332: 824-825.
57. Walton JM, Tougas G. Botulinum toxin use in pediatric esophageal achalasia: a case report. J Pediatr Surg 1997; 32: 916-917.
58. Cassidy MJ, Schiano TD, Adrain AL. Botulinum toxin injection for the treatment of syntomatic difuse esophageal spasm. Am J Gastroenterol 1996; 91: 1.884.
59. Choudhry U, Boyce HV. A prospective study of efficacy of botulinum toxin A (BTX) in patients with epiphrenic diverticula. Am J Gastroenterol 1996; 91: 1.885.
60. DeVault KR. Esophageal diverticulosis: a motility disorder responding to botulinum toxin injection. Am J Gastroenterol 1996; 91: 1.886.
61. Pasricha PJ, Miskovsky EP, Kalloo AN. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut 1994; 35: 1.319-1.321.
62. Kalloo AN, Pasricha PJ. Therapy of sphincter of Oddi dysfunction. Gastrointest Endosc Clin North Am 1996; 6: 117-125.
63. Bhutani MS. Gastrointestinal uses of botulinum toxin. Am J Gastroenterol 1997; 92: 929-933.
64. Langer JC, Birnbaum E. Preliminary experience with intrasphincteric botulinum toxin for persistent constipation after pull-through for Hirschsprung's disease. J Pediatr Surg 1997; 32: 1.059-1.061.
65. Albanese A, Bentivoglio AR, Cassetta E, Viggiano A, Maria G, Gui D. The use of botulinum toxin in the alimentary tract. Aliment Pharmacol Ther 1995; 9: 599-604.
66. Schouten WR, Briel JW, Auwerda JJ, Boerma MO. Anal fissure: new concepts in pathogenesis and treatment. Scand J Gastroenterol 1996; 31 (Supl 218): 78-81.
67. Mason PF, Watkins MJ, Hall HS, Hall AW. The management of chronic fissure in-ano with botulinum toxin. J R Coll Surg Edimburg 1996; 41: 235-238.
68. Jost WH. One hundred cases of anal fissure treated with botulin toxin: early and long-term results. Dis Colon Rectum 1997; 40: 1.029-1.032.
69. Janicke DM, Pundt MR. Anorectal disorders. Emerg Med Clin North Am 1996; 14: 757-788.
70. Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology 1991; 41: 1.185-1.188.
71. Trosch RM, Pullman SL. Botulinum toxin injections for the treatment of hand tremors. Mov Disord 1994; 9: 601-609.
72. Pahwa R, Busembark K, Swanson-Hyland EF, Dubinsky RM, Hubble JP. Botulinum toxin treatment of essential head tremor. Neurology 1995; 45: 822-824.
73. Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 1997; 12: 722-726.
74. Ludlov C, Sedory S, Fujita M, Naunton R. Treatment of voice tremor with botulinum toxin injection. Neurology 1989; 39 (Supl 1): 353.
75. Deusehl G, Lohle E, Heinen F, Lucking C. Ear click in palatal tremor: its origin and treatment with botulinum toxin. Neurology 1991; 41: 1.677-1.679.
76. Cheshire WP, Abashian SW, Mann JD. Botulunum toxin in the treatment of myofascial pain syndrome. Pain 1994; 59: 65-69.
77. Wolfe F, Simons DG, Fricton J, Bennett RM, Goldenberg DL, Gerwin R et al. The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J Rheumatol 1992; 40: 249-254.
78. Hobson D, Gladish D. Tensional and cervicogenic headache. Headache 1997; 37: 253-255.
79. Albanese A, Bentivoglio AR, Cassetta E, Viggiano A, Maria G, Gui D. The use of Botulinum toxin on smooth muscles. Eur J Neurol 1995; 2 (Supl 3): 29-33.
80. Giladi N, Honigman S. Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson's disease. Mov Disord 1997; 12: 1.085-1.086.
81. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. "Off" painfull dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995; 10: 333-336.
82. Albanese A, Maria G, Bentivoglio AR, Brisinda G, Cassetta E, Tonali P. Severe constipation in Parkinson's disease relieved by botulinum toxin. Mov Disord 1997; 12: 764-766.
83. Polo KB. Botulinum toxin A improves the rigidity in progressive supranuclear palsy. Ann Neurol 1994; 35: 237-239.
84. Parkinson K, Marion MH. Apraxia of lid opening. A focal eyelid dystonia: clinical study of 32 patients. Mov Disord 1994; 9: 610-615.
85. Piccione F, Mancini E, Parkinson T, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil 1997; 78: 525-529.
86. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583-609.
87. Charles PD, Davis TL, Shannon KM, Hook MA, Warner JS. Tongue protrusion dystonia: treatment with botulinum toxin. South Med J 1997; 90: 522-525.
88. Pranzatelli MR. Antidyskinetic drug therapy for pediatric movement disorders. J Child Neurol 1996; 11: 355-369.
89. Jankovik J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994; 9: 347-349.
90. Ivanhoe CB, Lai JM, Francisco GE. Bruxism after brain injury: successful treatment with botulinum toxin-A. Arch Phys Med Rehabil 1997; 78: 1.272-1.273.
91. Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjögren's syndrome: a preliminary report. J Rheumatol 1997; 24: 1.842-1.843.
92. Liguori R, Cordivari C, Lugaresi E, Montagna P. Botulinum toxin A improves muscle spasm and rigidity in stiff-person syndrome. Mov Disord 1997; 12: 1.060-1.063.
93. Sonies BC. Evaluation and treatment of speech and swallowing disorders associated with myopathies. Curr Opin Rheumatol 1997; 9: 486-495.
94. Brin MF, Stewart C, Blitzer A, Diamond B. Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology 1994; 44: 2.262-2.266.
95. Polo KB, Jabbari M. Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord 1994; 9: 233-235.
96. Brin MF, Vapnek JM. Treatment of vaginismus with botulinum toxin injections. Lancet 1997; 349: 252-253.
97. Morre HH, Keizer SB, Van Os JJ. Treatment of chronic tennis elbow with botulinum toxin. Lancet 1997; 349: 1.746.